INTERNATIONAL STUDIES ON DRUG ABUSE AND HIV/AIDS Release Date: January 29, 2001 RFA: RFA-DA-01-006 National Institute on Drug Abuse (http://www.nida.nih.gov/) Letter of Intent Receipt Date: February 28, 2001 Applicaton Receipt Date: March 28, 2001 THIS REQUEST FOR APPLICATIONS (RFA) USES THE "MODULAR GRANT" AND "JUST-IN- TIME" CONCEPTS. IT INCLUDES DETAILED MODIFICATIONS TO STANDARD APPLICATION INSTRUCTIONS THAT MUST BE USED WHEN PREPARING APPLICATIONS IN RESPONSE TO THIS RFA. PURPOSE The National Institute on Drug Abuse (NIDA) invites applications for international, cross-disciplinary research on HIV/AIDS, other blood-borne infections [i.e., hepatitis B virus (HBV), and hepatitis C virus (HCV)], tuberculosis (TB), and comorbid conditions and consequences in injecting and noninjecting drug users, their sexual partners, and their children. This RFA is intended to build on lessons learned in developed countries in response to the intertwined epidemics of drug abuse and the spread of HIV/AIDS and other infectious diseases. It seeks to foster cross-national and international research collaborations that, through both independent research and the recruitment, training, and mentoring of new, multi-disciplinary researchers, lead to the development, adaptation, replication, and evaluation of effective interventions and approaches to slow or reverse the spread of HIV and other infections in vulnerable drug-using populations. Epidemiologic studies on the dynamics of drug abuse and HIV demonstrate a continual need to reach new and emerging risk groups in diverse geographic settings with effective prevention interventions. Recent data indicate that injecting drug use is now a major mode of HIV transmission in many parts of the world. As many as 134 countries and territiories had documented cases of injecting drug use in 1999, compared with only 80 in 1992. Of this same group, 114 had reported HIV infection associated with drug injecting in 1999, compared with only 52 in 1992. In 1999, about two-thirds (23.3 million) of the 33.6 million people in the world living with HIV/AIDS live in sub-Saharan Africa. Historically, the epidemic in sub-Saharan Africa has been driven by heterosexual transmission, but there, as elsewhere, injecting and noninjecting drug use are becoming increasingly important - and in some areas, predominant - as rates of drug use continue to rise. Injecting and noninjecting drug use have synergistic effects on the spread of HIV and other infections to the general population, particularly when drug use is combined with high-risk, unprotected sex. Challenges for cross-national and international HIV research efforts lie in the diversity of risk groups and communities of drug users, the rapidly changing drug- and sex-related risk profiles of susceptible populations, the variability in global injecting and noninjecting drug use patterns, the complex interactions among behavioral, ethnic/racial, sociocultural, environmental, and biomedical factors that influence the initiation and progression of drug abuse and the spread of HIV and other infections, and the differences among developing and developed countries as to their understanding of the intertwined epidemics of drug abuse and HIV, their public health knowledge and experience, and their capacities to respond with durable, effective measures to contain the epidemics. This RFA will support cross-national and international research across the multiple disciplines of virology, etiology, therapeutics and vaccines, ethnography and epidemiology, and the behavioral and social sciences on: the acquisition, transmission, and prevention of HIV and other blood-borne infections in sexually active populations of injecting and noninjecting drug users, the clinical course and consequences of HIV and other health conditions in diverse communities of drug users, their sexual partners, and their children, the causes and consequences of differences in HIV-associated risks, morbidity, and mortality between men and women, adolescents and adults, and in majority and minority populations, and the design, development, adaptation, and evaluation of behavioral and biomedical prevention interventions to reduce the global scope and burden from drug use- and sex-related risk behaviors on the spread of HIV and other infectious diseases. Researchers are encouraged to utilize, adapt, and integrate complementary and multimethod approaches in their study designs, including those of epidemiology and ethnography, prevention science, virology, and clinical medicine. Established researchers are also urged to recruit new, domestic and foreign researchers to work on their projects, to provide training and mentoring to help achieve their project’s specific aims, and to nurture the career development and independence of new researchers with potential to enrich the multiple disciplines involved in preventing HIV and other infections in high-risk drug-using populations. HEALTHY PEOPLE 2010 The Public Health Services (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010," a PHS led national activity for setting priority areas. This RFA, "International Studies on Drug Abuse and HIV/AIDS," is related to one or more of the priority areas. Potential applicants may obtain a copy of "Healthy People 2010" at http://www.health.gov/healthypeople/. ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign for-profit and non- profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as Principal Investigators. MECHANISM OF SUPPORT The mechanism of support for this RFA will include the investigator-initiated research project (R01), small grant (R03), and exploratory/developmental (R21) award mechanisms. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. Applicants are also advised to contact NIDA program staff listed under INQUIRIES for additional information. Modular budgeting procedures apply for grants up to $250,000. See http://grants.nih.gov/grants/funding/modular/modular.htm for further information about modular budgets. The total project period for an application submitted in response to this RFA may not exceed five years for the R01, two years for the R03, and three years for the R21. Specific information and preparation guidelines for individual research mechanisms can be obtained under "Funding" from the NIDA home page at http://www.nida.nih.gov. FUNDS AVAILABLE NIDA intends to commit approximately $1,500,000 in FY 2001 to fund five to six new awards in response to this RFA. Because the nature and scope of the research proposed may vary, it is anticipated that the size of each award will also vary. Although the financial plans of the Institute provide support for this program, awards pursuant to this RFA are contingent upon the availability of funds and the receipt of a sufficient number of applications of outstanding scientific and technical merit. RESEARCH OBJECTIVES Background Research has shown that major modes of transmission of HIV and other blood- borne infections in drug-using populations are through multiperson reuse or sharing of contaminated syringes and other injection equipment and through unprotected sexual contact with infected individuals (often in conjunction with drug use, including the noninjecting - smoking or inhaling use of heroin and crack cocaine). Since the AIDS epidemic first emerged in the 1980s, researchers have designed and assessed a range of prevention intervention strategies to reduce transmission risks for HIV and other infections in drug users, their sexual partners, and their children. Single and combined components of different HIV prevention interventions and services have been found to be effective in reaching at-risk populations of drug users to help them reduce their risks of acquiring or transmitting HIV and other infections. Over time, these strategies and/or their components have been implemented among diverse risk groups (e.g., men and women, adolescents and adults, and in majority and minority populations) in multiple sites, in different regions of the United States, and in different countries. In some instances, HIV prevention interventions that originated in other countries have been adapted and implemented in the U.S. Cumulative research findings have shown that decreases in the prevalence of risk behaviors, and conversely, increases in protective behaviors, are associated with declining incidence in HIV and other blood-borne infections in at-risk populations. Despite the significant advances that have been made, however, HIV and other infectious diseases continue to spread among drug-using populations in the U.S. and worldwide. The cumulative evidence shows that no single approach is sufficient to avert new HIV and other infections in all drug users and their sexual partners. Research gaps remain in a number of key areas, including but not limited to our understanding of the epidemiology of risks for HIV/AIDS in drug-using populations and others at risk, the clinical course and consequences of HIV and co-occurring infections associated with continual risky drug use and sexual practices, the individual (e.g., age, gender, race/ethnicity) and environmental (e.g., social, economic, cultural) factors that influence attitudes, beliefs, and behaviors related to drug use and risky sex, and the impact of drug abuse, HIV/AIDS, and related infectious diseases on diverse community populations throughout the world. Cross- national and international studies are needed to address these research gaps and to develop and implement comprehensive, cost-effective interventions to prevent the spread of HIV and other infections among drug-using populations. Areas of Research Focus This initiative will support cross-national and international research that includes but is not limited to the following interrelated areas: 1) Risk-factor epidemiology of HIV and co-occurring blood-borne infections in drug-using men and women, in their sexual partners, and in their children. 2) Behavioral dynamics and drug use-related processes associated with the acquisition and transmission of HIV and other infections, including individual, social, environmental, cultural, economic, gender-based, and other factors which influence transitions between noninjecting and injecting drug use. 3) Adaptation, replication, and evaluation of outreach-based prevention interventions to reduce risk behaviors and avert incident HIV and other infections in high-risk populations. 4) Development and testing of innovative, durable, and cost-effective behavioral and biomedical approaches to prevent disease transmission and enhance adherence with risk reduction interventions and available drug and medical treatment regimens. 5) Comparative studies of the single and combined components of various prevention/ intervention strategies and services among drug-using men and women and their sexual partners in diverse international settings, including studies of their differential impacts on the incidence, prevalence, and transmission of HIV and other blood-borne infections, their cost- effectiveness, and the nature and extent of their linkages to other social, health, and medical services. 6) Virologic, immunologic, genetic, and drug use factors and the mechanisms by which they may influence susceptibility, recovery and persistence, and progression of HIV and other diseases in drug-using men and women, in their sexual partners, and in their children. 7) Socioeconomic and demographic characteristics, sexual and drug-using behaviors, HIV virologic and immunologic status, and the health and medical consequences of HIV and other blood-borne infections in drug-using populations and others at risk. 8) Development of innovative, comprehensive interventions to improve access to and delivery of vaccines (e.g., hepatitis A and B vaccines), antiretroviral and other therapeutic agents, routine screening services for sexually transmitted diseases (STDs), and HIV testing and counseling services to drug-using populations and others at risk. 9) Comparative effectiveness and sustainability of prevention and treatment interventions in diverse international settings, including studies of access and adherence to multiple types of behavioral and therapeutic interventions, and the development of improved, accessible clinical management approaches. 10) Bioethical considerations in research methodologies, and in the design and implementation of culturally appropriate, available, and affordable prevention interventions, including counseling and testing services, medical care, and drug treatment to drug-using men and women, their sexual partners, and their children infected with HIV and other infectious diseases. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their sub-populations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification are provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing research involving human subjects should read the updated "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research," published in the NIH Guide for Grants and Contracts on August 2, 2000 (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-048.html), a complete copy of the updated Guidelines are available at http://grants.nih.gov/grants/funding/women_min/guidelines_update.htm. The revisions relate to NIH defined Phase III clinical trials and require: a) all applications or proposals and/or protocols to provide a description of plans to conduct analyses, as appropriate, to address differences by sex/gender and/or racial/ethnic groups, including subgroups if applicable, and b) all investigators to report accrual, and to conduct and report analyses, as appropriate, by sex/gender and/or racial/ethnic group differences. Inasmuch as laboratory, field, and clinical research findings on HIV/AIDS suggest that there are gender differences in a number of important areas, investigators are encouraged to examine sex differences in their study designs. INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of NIH that children (i.e., individuals under the age 21) must be included in all human subjects research conducted or supported by the NIH unless there are scientific and ethical reasons not to include them. This policy applies to all initial (Type 1) applications submitted for receipt dates after October 1, 1998. All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines on the Inclusion of Children as Participants in Research Involving Human Subjects" that was published in the NIH Guide for Grants and Contract, March 6, 1998, and is available at the following URL address: http://grants.nih.gov/grants/guide/notice-files/not98-024.html. Investigators also may obtain copies of these policies from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning these policies. NATIONAL ADVISORY COUNCIL ON DRUG ABUSE RECOMMENDED GUIDELINES FOR THE ADMINISTRATION OF DRUGS TO HUMAN SUBJECTS The National Advisory Council on Drug Abuse recognizes the importance of research involving the administration of drugs to human subjects and has developed guidelines relevant to such research. Potential applicants are encouraged to obtain and review the recommendations before submitting an application that will administer compounds to human subjects. The guidelines are available on NIDA’s home page at http://www.nida.nih.gov/ or may be obtained by calling (301) 443-2755. HIV/AIDS COUNSELING AND TESTING POLICY FOR THE NATIONAL INSTITUTE ON DRUG ABUSE Researchers funded by NIDA who are conducting research in community outreach settings, clinics, hospital settings, or clinical laboratories and have ongoing contact with clients at risk for HIV infection, are strongly encouraged to provide HIV risk reduction education and counseling. HIV counseling should include offering HIV testing available on-site or by referral to other HIV testing services. Persons at risk for HIV infection include injecting drug users, crack cocaine users, and sexually active drug users and their sexual partners. For more information see http://grants.nih.gov/grants/guide/notice-files/NOT-DA-01-001.html. URLS IN NIH GRANT APPLICATIONS OR APPENDICES All applications and proposals for NIH funding must be self-contained within specified page limitations. Unless otherwise specified in an NIH solicitation, Internet addresses (URLs) should not be used to provide information necessary to the review because reviewers are under no obligation to view the Internet sites. Reviewers are cautioned that their anonymity may be compromised when they directly access an Internet site. LETTER OF INTENT Prospective applicants are asked to submit a letter of intent that includes a descriptive title of the proposed research, the name, address, and telephone number of the Principal Investigator, the identities of other all personnel and participating institutions, and the number and title of the RFA in response to which the application is being submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows NIDA staff to estimate the potential review workload and plan the review. The letter of intent is to be sent to: Director, Office of Extramural Affairs National Institute on Drug Abuse 6001 Executive Boulevard, Room 3158, MSC 9547 Bethesda, MD 20892-9547 Telephone: (301) 443-2755 FAX: (301) 443-0538 APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 4/98) is to be used in applying for these grants. Application kits are available at most institutional offices of sponsored research and may be obtained from the Division of Extramural Outreach and Information Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892- 7910, telephone (301) 710-0267, E-mail: GrantsInfo@nih.gov. SPECIFIC APPLICATION INSTRUCTIONS FOR MODULAR GRANTS The modular grant concept establishes specific modules in which direct costs may be requested, as well as a maximum level for requested budgets. Only limited budgetary information is required under this approach. The just-in-time concept allows applicants to submit certain information only when there is a possibility for an award. It is anticipated that these changes will reduce the administrative burden for the applicants, reviewers, and Institute staff. The research grant application form PHS 398 (rev. 4/98) is to be used in applying for these grants, with the modifications noted below. BUDGET INSTRUCTIONS Modular grant applications will request direct costs in $25,000 modules, up to a total direct cost request of $250,000 per year. (Applications that request more than $250,000 direct costs in any year must follow the traditional PHS 398 application instructions.) The total direct costs must be requested in accordance with the program guidelines and the modifications made to the standard PHS 398 application instructions described below. PHS 398 FACE PAGE - Items 7a and 7b should be completed, indicating Direct Costs (in $25,000 increments up to a maximum of $250,000) and Total Costs [Modular Total Direct plus Facilities and Administrative (F&A) costs] for the initial budget period. Items 8a and 8b should be completed indicating the Direct and Total Costs for the entire proposed period of support. DETAILED BUDGET FOR THE INITIAL BUDGET PERIOD - Do not complete Form Page 4 of the PHS 398. It is not required and will not be accepted with the application. BUDGET FOR THE ENTIRE PROPOSED PERIOD OF SUPPORT - Do not complete the categorical budget table on Form Page 5 of the PHS 398. It is not required and will not be accepted with the application. NARRATIVE BUDGET JUSTIFICATION - Prepare a Modular Grant Budget Narrative page (see http://grants.nih.gov/grants/funding/modular/modular.htm for sample pages). At the top of the page, enter the total Direct Costs requested for each year. This is not a Form page. Under Personnel, list all project personnel, including their names, percent of effort, and roles on the project. No individual salary information should be provided. However, the applicant should use the NIH appropriation language salary cap and the NIH policy for graduate student compensation in developing the budget request. For Consortium/Contractual costs, provide an estimate of total costs (Direct plus F&A) for each year, each rounded to the nearest $1,000. List the individuals/organizations with whom consortium or contractual arrangements have been made, the percent effort of all personnel, and their role on the project. Indicate whether the collaborating institution is foreign or domestic. The total cost for a consortium/contractual arrangement is included in the overall requested Modular Direct Cost amount. Include the letter of intent to establish a consortium. Provide an additional narrative budget justification for any variation in the number of modules requested. BIOGRAPHICAL SKETCH - The Biographical Sketch provides information used by reviewers in the assessment of each individual"s qualifications for a specific role in the proposed project, as well as to evaluate the overall qualifications of the research team. A biographical sketch is required for all key personnel, following the instructions below. No more than three pages may be used for each person. A sample biographical sketch may be viewed at: http://grants.nih.gov/grants/funding/modular/modular.htm. - Complete the educational block at the top of the Form page, - List position(s) and any honors, - Provide information, including overall goals and responsibilities, on research projects ongoing or completed during the last three years, and - List selected peer-reviewed publications with full citations. CHECKLIST - This page should be completed and submitted with the application. If the F&A rate agreement has been established, indicate the type of agreement and the date. All appropriate exclusions must be applied in the calculation of the F&A costs for the initial budget period and all future budget years. The applicant should provide the name and phone number of the individual to contact concerning fiscal and administrative issues if additional information is necessary following the initial review. The RFA label available in the PHS 398 (rev. 4/98) application form must be affixed to the bottom of the face page of the application. Type the RFA number on the label. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the title and number of this RFA must be typed in Item 2 on the face page of the application form, and the YES box must be marked. The sample RFA label available at: http://grants.nih.gov/grants/funding/phs398/label-bk.pdf has been modified to allow for this change. Please note this is in pdf format. Submit a signed, typewritten original of the application, including the Checklist, and three signed photocopies in one package to: CENTER FOR SCIENTIFIC REVIEW NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710 BETHESDA, MD 20892-7710 BETHESDA, MD 20817 (for express/courier service) At the time of submission, two additional copies of the application must be sent to: Director, Office of Extramural Program Review National Institute on Drug Abuse 6001 Executive Boulevard, Room 3158, MSC 9547 Bethesda, MD 20892-9547 Rockville, MD 20852 (for express/courier service) Applications must be received by the receipt date listed in the heading of this RFA. . If an application is received after that date, it will be returned to the applicant without review. The Center for Scientific Research (CSR) will not accept any application in response to this RFA that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. The CSR will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed for completeness by the CSR and responsiveness by NIDA. Incomplete and/or non-responsive applications will be returned to the applicant without further consideration. Applications that are complete will be evaluated for scientific and technical merit by a peer review group convened in accordance with the standard NIH peer review procedures. As part of the initial merit review, all applications will receive a written critique and undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of the applications under review, will be discussed, assigned a priority score, and receive a second level review by the National Advisory Council on Drug Abuse. REVIEW CRITERIA The goals of NIH-supported research are to advance the understanding of biological systems, improve the control of disease, and enhance health. In the written comments, reviewers will be asked to discuss the following aspects of the application in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed and considered in assigning the overall score, weighting them as appropriate for each application. Note that the application does not need to be strong in all categories to be judged likely to have major scientific impact and thus deserve a high priority score. (1) Significance: Are the goals and objectives of this application relevant to this RFA? Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of these studies on the concepts or methods that drive this field? (2) Approach: Are the conceptual framework, design, methods, and analyses adequately developed, well-integrated, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics? (3) Innovation: Does the project employ novel concepts, approaches, or method? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies? (4) Investigator: Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)? (5) Environment: Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support? In addition to the above criteria, in accordance with NIH policy, all applications will also be reviewed with respect to the following: - The adequacy of plans to include both genders, minorities, and their subgroups, as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated. - The adequacy of plans to make data available to other investigators in a timely fashion. - The reasonableness of the proposed budget and duration in relation to the proposed research. - The adequacy of the proposed protection for humans, animals, or the environment, to the extent they may be adversely affected by the project proposed in the application. - The adequacy of plans for including children as appropriate for the scientific goals of the research. Schedule: Letter of Intent: February 28, 2001 Application Receipt Date: March 28, 2001 Peer Review Date: June/July 2001 Council Review: September 2001 Earliest Start Date: September 30, 2001 AWARD CRITERIA Award criteria that will be used to make award decisions include scientific merit as determined by peer review, availability of funds, and programmatic priorities. INQUIRIES Inquiries concerning this RFA are strongly encouraged. The opportunity to clarify issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Helen Cesari, M.Sc. Center on AIDS and Other Medical Consequences of Drug Abuse National Institute on Drug Abuse 6001 Executive Boulevard, Room 5198, MSC 9593 Bethesda, MD 20892-9593 Telephone : (301) 402-1918 FAX : (301) 443-4100 E-mail: hc30x@nih.gov Direct inquiries regarding fiscal matters to: Gary Fleming, J.D., M.A. Grants Management Branch National Institute on Drug Abuse 6001 Executive Boulevard, Room 3131, MSC 9541 Bethesda, MD 20892-9541 Telephone: (301) 443-6710 FAX : (301) 594-6847 E-mail: gf6s@nih.gov Direct inquiries regarding review matters to: Teresa Levitin, Ph.D. Director Office of Extramural Affairs National Institute on Drug Abuse 6001 Executive Boulevard, Room 3158, MSC 9547 Bethesda, MD 20892-9547 Telephone: (301) 443-2755 FAX: (301) 443-0538 E-mail: tl25u@nih.gov AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.279. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and are administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices



NIH Office of Extramural Research Logo
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®



Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.